WARREN, N.J., June 22 /PRNewswire/ -- MonoSol Rx, the developer of PharmFilm® drug delivery technology, today announced the appointment of Eric Dadey, Ph.D. to the position of Senior Vice President, Pharmaceutical Development. Effective immediately, Dr. Dadey will report to A. Mark Schobel, President and Chief Executive Officer. He will be responsible for leading the Company’s product development and analytical activities.
Mr. Schobel said, “On behalf of our team I would like to welcome Dr. Dadey to MonoSol Rx. We look forward to Eric contributing to the company’s continued success by utilizing his significant level of expertise and experience in the pharmaceutics field and that of polymeric drug delivery systems. His leadership will be instrumental in the advancement of our existing product pipeline and the identification of new applications for our PharmFilm® drug delivery platform.”
Prior to joining MonoSol Rx, Dr. Dadey served as Vice President, Preclinical Development at Transave Inhalation Biotherapeutics, where he supervised toxicological and efficacy evaluations of the company’s product portfolio. Prior to that, Eric worked for QLT USA, Inc. as Vice President Drug Delivery, responsible for all research and development activities utilizing its flagship polymer-based sustained-release delivery technology.
Between 1992 and 2004, Dr. Dadey held positions of increasing responsibility at Atrix Laboratories, Nycomed Salutar and ACCESS Pharmaceuticals, where he led formulation and commercial launch efforts surrounding polymer and biodegradable polymer drug delivery systems.
Dr. Dadey’s career also included a Postdoctoral Fellowship at the University of Kentucky as well as an Assistant Professorship of Pharmaceutics in the College of Pharmacy at the University of Illinois at Chicago. Dr. Dadey earned his B.S. and M.S. in Chemistry at Western Kentucky University, and an M.S. in Organic Chemistry and Ph.D. in Pharmaceutical Sciences from the University of Kentucky.
Dr. Dadey said, “I look forward to working with the MonoSol Rx team to make the PharmFilm® technology the first choice for film drug delivery.”
About MonoSol Rx
MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm® technology to deliver unique proprietary pharmaceutical drug films. PharmFilm® is designed to benefit patients by improving the convenience, efficacy, and compliance of new and currently marketed drugs. The Company’s leadership in film drug delivery is supported by strong intellectual property, a portfolio of commercialized over-the-counter (OTC) drug products, and a development pipeline of prescription formulations based on PharmFilm® technology. With a vertically integrated development and production infrastructure, MonoSol Rx has the capacity to manufacture OTC drug products for near-term revenues that fund prescription product development programs that will generate long-term value.
The Company’s commercialization strategy for all PharmFilm® products is to partner with the innovator, other specialty pharma or leading consumer products companies that can sell-in and manage product sales and marketing. For existing and future partners, PharmFilm® formulations represent revenue-life cycle extensions for products with patent lives that have expired or are approaching expiration. PharmFilm® is also a tool to help sales and marketing partners differentiate in competitive markets while offering unique advantages over drugs dosed by traditional tablets, capsules and orally disintegrating tablets (ODTs).
Contacts: | ||
MonoSol Rx: | The Ruth Group | |
Keith Kendall | Jason Rando (media) | |
Chief Financial Officer | (646) 536-7025 | |
(732) 564-5000 | jrando@theruthgroup.com | |
Sara Pellegrino (investors) | ||
(646) 536-7002 | ||
spellegrino@theruthgroup.com | ||
SOURCE MonoSol Rx
